ArticleCureus2025
An Unusual Case of Primary Plasma Cell Leukemia Presenting As Pericardial Effusion.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasma cell leukemia represents the rarest form of plasma cell dyscrasias arising from monoclonal proliferation of plasma cells in peripheral blood. Its aggressive natural history raises a significant therapeutic challenge. We present a case of a 58-year-old female who presented with a cough accompanied by exertional dyspnea. Further radiological investigations revealed a circumferential pericardial effusion. A pericardiocentesis was performed, resulting in the drainage of 650 cc of hemorrhagic pericardial fluid. Cytology revealed monoclonal plasma cells expressing CD38 and CD138 with cytoplasmic lambda light chain restriction. A bone marrow biopsy disclosed a hypercellular marrow with a monoclonal plasma cell population of 33%. Treatment was initiated with intravenous dexamethasone and weekly subcutaneous injections of bortezomib, followed by outpatient cycles consisting of bortezomib, lenalidomide, daratumumab, and dexamethasone, with a good initial response. However, five months later, the plasma cell leukemia became refractory to treatment, and the patient passed away from septic shock secondary to community-acquired pneumonia. This case illustrates the variable presentations of plasma cell leukemia, as well as its poor prognosis. Further research is warranted to optimize therapeutic regimens and enhance overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.